ACA
EIGR

Atlas Capital Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Atlas Capital Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33
Closed -$6.68K – 970
2021
Q3 		$6.68K Hold
33
– – ﹤0.01% 777
2021
Q2 		$8.52K Hold
33
– – ﹤0.01% 765
2021
Q1 		$8.85K Hold
33
– – ﹤0.01% 695
2020
Q4 		$12.3K Buy
+33
New +$9.47K ﹤0.01% 576
2020
Q3 		– Sell
-33
Closed -$9.6K – 620
2020
Q2 		$9.6K Buy
+33
New +$9.73K ﹤0.01% 612

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atlas Capital Advisors's EIGR Position: Q4 2021 in Review

Atlas Capital Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 33 shares — an estimated $6.68K sold.

Atlas Capital Advisors first reported a position in EIGR in Q2 2020 and held it in 5 quarters. The position peaked at $12.3K in Q4 2020. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • Atlas Capital Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Atlas Capital Advisors sold 33 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $6.68K.
  • Atlas Capital Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 5 quarters.
  • Atlas Capital Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $12.3K in Q4 2020.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Atlas Capital Advisors's 13F filing for Q4 2021, filed 1 Feb 2022.